BHVN achève l'inscription à une étude sur l'obésité

What happened: Biohaven Pharmaceuticals (BHVN) completed enrollment in a Phase 2 obesity study for its drug candidate, taldefgrobep alfa, on March 19, 2026. This follows analyst Ken Cacciatore from TD Cowen increasing his price target on BHVN from $15 to $30 on March 11, citing encouraging data from the company's Azetukalner program.

Market impact: The biopharmaceutical sector, particularly small-cap stocks, is affected. BHVN's stock surged on the news, driven by increased investor confidence in the company's pipeline. Hedge funds have also shown interest, with BHVN appearing in the top 7 small-cap healthcare stocks to buy.

What to watch next: Upcoming catalysts include the release of interim data from the taldefgrobep alfa obesity study in Q4 2026, regulatory decisions on Azetukalner, and BHVN's Q2 2026 earnings report, scheduled for mid-May.